LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)

Katerina Maliarchuk; Andrey Ganul; Bogdan Borisyuk; Leonid Bororov; Anatoly Shevchenko; Vladimir Sovenko; Lubov Kutsenko

doi:10.5114/hpc.2022.121417

eISSN: 2354-0265
ISSN: 2353-6942

Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO

Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2022
vol. 16

Send email

Copy url:

DISEASES AND PROBLEMS DISTINGUISHED BY WHO AND FAO

abstract:

Original paper

LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)

Katerina Maliarchuk

¹

,

Andrey Ganul

²

,

Bogdan Borisyuk

²

,

Leonid Bororov

²

,

Anatoly Shevchenko

²

,

Vladimir Sovenko

²

,

Lubov Kutsenko

³

Department of Oncology, the Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine

Department of Chest and Mediastinal, National Cancer Institute, Kyiv, Ukraine

Department of Statistics, National Cancer Institute, Kyiv, Ukraine

Health Prob Civil. 2022; 16(4): 302-311

DOI: https://doi.org/10.5114/hpc.2022.121417

Online publish date: 2022/12/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Maliarchuk K, Ganul A, Borisyuk B, et al. LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT). Health Problems of Civilization. 2022;16(4):302-311. doi:10.5114/hpc.2022.121417.

APA

Maliarchuk, K., Ganul, A., Borisyuk, B., Bororov, L., Shevchenko, A.,  & Sovenko, V. et al. (2022). LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT). Health Problems of Civilization, 16(4), 302-311. https://doi.org/10.5114/hpc.2022.121417

Chicago

Maliarchuk, Katerina, Andrey Ganul, Bogdan Borisyuk, Leonid Bororov, Anatoly Shevchenko, Vladimir Sovenko,  and Lubov Kutsenko. 2022. "LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)". Health Problems of Civilization 16 (4): 302-311. doi:10.5114/hpc.2022.121417.

Harvard

Maliarchuk, K., Ganul, A., Borisyuk, B., Bororov, L., Shevchenko, A., Sovenko, V.,  and Kutsenko, L. (2022). LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT). Health Problems of Civilization, 16(4), pp.302-311. https://doi.org/10.5114/hpc.2022.121417

MLA

Maliarchuk, Katerina et al. "LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)." Health Problems of Civilization, vol. 16, no. 4, 2022, pp. 302-311. doi:10.5114/hpc.2022.121417.

Vancouver

Maliarchuk K, Ganul A, Borisyuk B, Bororov L, Shevchenko A, Sovenko V et al. LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT). Health Problems of Civilization. 2022;16(4):302-311. doi:10.5114/hpc.2022.121417.

PlumX metrics:

Background
This work is а comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT).

Material and methods
Three groups of 65 people were selected. The first group received NCT, the second group – NCT, and the third group – NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria.

Results
The statistical criterion for NCRT in relation to NCT was -3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was -2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307).

Conclusions
Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.

keywords:

LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT)

Katerina Maliarchuk 1 , Andrey Ganul 2 , Bogdan Borisyuk 2 , Leonid Bororov 2 , Anatoly Shevchenko 2 , Vladimir Sovenko 2 , Lubov Kutsenko 3

neoadjuvant therapy, pneumonectomy, lobectomy, non-small cell lung cancer, overall survival

Katerina Maliarchuk

¹

,

Andrey Ganul

²

,

Bogdan Borisyuk

²

,

Leonid Bororov

²

,

Anatoly Shevchenko

²

,

Vladimir Sovenko

²

,

Lubov Kutsenko

³